ZF874 + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha1 Anti-Trypsin Deficiency
Conditions
Alpha1 Anti-Trypsin Deficiency
Trial Timeline
Aug 3, 2020 → Sep 12, 2022
NCT ID
NCT04443192About ZF874 + Placebo
ZF874 + Placebo is a phase 1 stage product being developed by Centessa Pharmaceuticals for Alpha1 Anti-Trypsin Deficiency. The current trial status is terminated. This product is registered under clinical trial identifier NCT04443192. Target conditions include Alpha1 Anti-Trypsin Deficiency.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04443192 | Phase 1 | Terminated |
Competing Products
6 competing products in Alpha1 Anti-Trypsin Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VX-864 + Placebo | Vertex Pharmaceuticals | Phase 2 | 51 |
| CE1226 | CSL | Approved | 84 |
| Alpha1-proteinase inhibitor | CSL | Approved | 84 |
| Alpha-1 15% + Liquid Alpha1-Proteinase Inhibitor (Human) | Grifols | Phase 1/2 | 38 |
| Alpha-1 MP | Grifols | Phase 1/2 | 38 |
| Alpha-1 MP | Grifols | Phase 1/2 | 38 |